A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).

Cancer Res Treat · 2023 · PMC10645518 · PMID 37232070

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a small phase 3 trial of 50 patients aged ≥ 70 years with MRGC, capecitabine plus oxaliplatin combination chemotherapy showed a trend of increased survival benefit compared with capecitabine monotherapy as first-line chemotherapy [ 14 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.